Überlebensrate von Tumoren

Überlebensrate menschlichen Tumorerkrankungen: Letalität

allgemeines

Während die Mortalität die Zahl der Todesfälle in einer Bevölkerung unabhängig von der Zahl der Erkrankten beschreibt, bezeichnet die Letalität die Wahrscheinlichkeit, eine Erkrankung nicht zu überleben.

Die Überlebensrate ist die Umkehrfunktion der Letalität: die Wahrscheinlichkeit, eine Erkrankung zu überleben.

CONCORD-2 (2)

Analyse von 25,7 Millionen Tumorpatienten aus 279 bevölkerungsbasieren Tumorregistern aus 67 Ländern

Tumor	Patienten	5a-surv hoch	mittel	gering
Magen	1 645 596	South Korea (58%), Japan (54%)	30–39% in Austria, Belgium, China, Germany, Iceland, Italy, Portugal, Switzerland, Taiwan.	18–19% Denmark, Malta, Poland, UK
colon cancer	3 613 067	>60%: North America, Oceania, 12 European countries, and a few countries in Central and South America and Asia	40–49%: Argentina, Bulgaria, Chile, Colombia, Latvia, Russia,	<40%: India, Indonesia, and Mongolia.
rectal cancer	1 413 861	>70% Cyprus, Iceland, and Qatar,	60–69% South Korea, North America, Oceania, and nine European countries	India (29%)
liver cancer	894 449	-	>20% Japan, South Korea, and Taiwan	< 10%) in Colombia, Denmark, Estonia, Finland, India, Malta, Mongolia, Norway, Russia, Slovenia, Thailand, and the UK.
lung cancer	5 294 261	Japan (30%), Israel (24%)	10–20%	< 10% Bulgaria, Lithuania, Mongolia, Thailand, 2%: Libya
breast cancer	5 486 928	>80% 34 countries	Malaysia (68%) and India (60%)	Mongolia (57%) and South Africa (53%)
cervical cancer	602 225	>70% Iceland, Mauritius, Norway, South Korea, and Taiwan	60–69%.	Libya (Benghazi, 39%) and India (Karunagappally, 46%).
prostate cancer	4 999 267	90% or higher in Austria, Belgium, Brazil, Canada, Cyprus, Ecuador, Finland, France, Germany, Israel, Italy, Lithuania, Puerto Rico, and the USA	80–89% in 19 countries in Central and South America, Asia, Europe, and Oceania.	Libya and Mongolia 40–41%.
leukaemia in adults	873 588	50–60% in 21 countries in North America, west Asia, Europe, and Oceania	33% in Turkey to 53% in Qatar, 40% in Indonesia	19% in Japan to 23% in South Korea and Taiwan, 7% in Jordan

CONCORD (3)

Erste Analyse der CONCORD-Gruppe

EUROCARE-5 (4)

European cancer registry study on survival

Überlebensraten in 29 europäischen Ländern 2000–07.

SurcCan-2 (5)

cancer survival in Africa, Asia, the Caribbean, and Central America

Überlebensraten in Ländern mit geringem oder mittlerem Einkommen 1990–2001

JCBP (6)

International Cancer Benchmarking Partnership

Überlebensraten in 6 Ländern mit hohem Einkommen 1995–2007

Erkrankung

Quellen

1.) Allemani C, et al. für die CONCORD Working Group:
Global surveillance of cancer survival 1995–2009:analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
www.thelancet.com Published online 2014 http://dx.doi.org/10.1016/S0140-6736(14)62038-9

2.) Cutler SJ, ed.:
International symposium on end results of cancertherapy (NCI monograph 15).
Bethesda: National Cancer Institute,1964.

3.) Coleman MP, et al. and the CONCORD Working Group:
Cancer survival in five continents: a worldwide population-based study (CONCORD).
Lancet Oncol 9(2008): 730–56

4.) De Angelis R, et al. and the EUROCARE-5 Working Group:
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study.
Lancet Oncol 15(2014): 23–34.

5.) Sankaranarayanan R, et al.:
Cancer survival in Africa, Asia, and Central America: a population-based study.
Lancet Oncol 11(2010): 165–73.

6.) Coleman MP, et al., and the ICBP Module 1 Working Group:
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.
Lancet 377(2011): 127–38.

Impressum Zuletzt geändert am 21.12.2013 12:28